Durham is Controlling Partner and Director brain damage and neurocognitive regeneration for The Mosaic Neuroscience Group in Santa Fe and Roswell New Mexico. He is also the founder of Neurocognitive Therapy – a novel integrative rehabilitative method of improving attention, storage, speech, sensory and visuo-spatial integration in brain injury patients. An interview with Professor WisdenDuring an informal briefing between 11:00 a.m. And 1:00 p.m., Dr. Durham will address the basic mechanisms of TBI and describe the clinical importance of categorizing TBI as either combat-sustained or noncombat sustained to optimize treatment outcomes.Some of the genes in question have a known activity in melanoma, whereas additional genes identified are also previously been shown to be involved in other cancers. Furthermore, a biological pathway associated with the expression of the genes was recognized: Two proteins where proven to intervene in the process of DNA replication. Both of these proteins represent potential targets for the development of fresh therapies for the individuals that fall within the group with bad prognosis. The findings enable a more accurate medical diagnosis of melanoma and can allow patients to make a even more informed choice concerning whether or not to be a part of clinical trials.